This is decidedly good news, but given that pembrolizumab already generates over $25 billion a year in revenue… in the near term, this coming approval will not materially boost that total — all by itself.

But this certainly continues the impressive winning streak — against a wide array of solid organ tumors / cancers, where Keytruda^® is now greatly extending survival odds, and quality of life durations. Here’s the latest, from a Merck presser this morning:

…[Rahway] announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (carboplatin and paclitaxel), followed by KEYTRUDA as a single agent for the treatment of patients with primary advanced or recurrent endometrial carcinoma….

The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 21, 2024….

Onward, into the warm sunshine now — grinning. Be excellent to one another.

नमस्ते